Printer Friendly

AGREEMENT SIGNED FOR RESEARCH COLLABORATION BETWEEN BIOCHEM PHARMA AND THE BIOTECHNOLOGY RESEARCH INSTITUTE OF NRC

 AGREEMENT SIGNED FOR RESEARCH COLLABORATION BETWEEN BIOCHEM PHARMA
 AND THE BIOTECHNOLOGY RESEARCH INSTITUTE OF NRC
 LAVAL, Quebec, Aug. 24 /PRNewswire/ -- BioChem Pharma Inc. (NASDAQ: BCHXF) and the Biotechnology Research Institute of the National Research Council of Canada (BRI) today signed a strategic agreement to collaborate on research into cardiovascular diseases.
 This agreement, reached last April 3, involves a three-year joint research program valued at $6.6 million, and may be renewed for another two years. The collaboration between the Institute and BioChem will accelerate research into a new generation of anti-thrombin compounds, discovered by the BRI, with potential application for the treatment of cardiovascular diseases. The worldwide market for anti-thrombin products is estimated at $500 million a year.
 This collaboration represents an important milestone in cardiovascular research in Canada. The combined efforts of these two organizations will accelerate work already in progress while allowing both to explore other avenues with potential application to cardiovascular diseases and, possibly, the area of neuro-degenerative diseases, including Alzheimer's.
 BioChem will obtain exclusive worldwide commercial rights to discoveries resulting from the research program, while the company will provide partial funding for the research undertaken by the BRI. In addition, BioChem will contribute its medicinal chemistry expertise in the area of synthetic peptide technology to the research program as well as pharmacological evaluation. It will also be responsible for the development and eventual commercialization of this new drug.
 The BRI will contribute to the research program in protein engineering and biomolecular modelling, areas in which it has an international reputation, and in which its expertise led to the discovery of this new compound.
 BioChem Pharma Inc. is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. The company's shares are listed on the Montreal and Toronto stock exchanges (BCH) and on the NASDAQ stock market (BCHXF).
 The Biotechnology Research Institute of the National Research Council is the largest biotechnology research institute in Canada dedicated to R & D into the industrial development of biotechnological products and processes. Its research programs are in the areas of bio- engineering and molecular biology. The BRI, which is located in Montreal, also has a major pilot plant facility for the scale-up of biopharmaceutical products.
 -0- 8/24/92
 /CONTACT: Dr. Francesco Bellini, president and chief executive officer of BioChem Pharma, Inc. 514-681-1744, or Dr. Maurice Brossard, vice president and director general of Biotechnology Research Institute National Research Council, Canada, 514-496-6101, or Michele Roy/Gerard Berube of National Public Relations, Inc. 514-843-7171, for BioChem Pharma/
 (BCHXF) CO: BioChem Pharma Inc.; Biotechnology Research Institute ST: Quebec IN: MTC SU:


DC-OS -- NY074 -- 2789 08/24/92 18:27 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1992
Words:448
Previous Article:AMMIRATI & PURIS SELECTED AS NEW ADVERTISING AGENCY FOR MASTERCARD
Next Article:BARNETT WORKS TO RESTORE SERVICES AFTER HURRICANE
Topics:


Related Articles
STRATEGIC RESEARCH COLLABORATION BETWEEN BIOCHEM PHARMA AND THE BIOTECHNOLOGY RESEARCH INSTITUTE IN THE AREA OF CARDIOVASCULAR DISEASES
BIOCHEM PHARMA AND GLAXO EXTEND RESEARCH AGREEMENT
BIOCHEM PHARMA OBTAINS LICENSE ON SECOND LOOK(TM) COMPUTER-BASED BREAST CANCER DETECTION SYSTEM
Structural Bioinformatics Inc. Generates Antiviral Lead Compound From Gene Sequence to Achieve Milestone in BioChem Pharma Collaboration.
Microbiotix and BioChem Pharma Enter Into Collaboration to Develop Novel Antibiotic Agents.
Biochem Pharma Announces Development Collaboration and Licensing Agreement With Cytovax Biotechnologies@.
Biochem Pharma Announces Collaboration and Licensing Agreement With Maxim Pharmaceuticals For a Series of Anticancer Compounds.
Expanding BioChem's oncology platform - BioChem Pharma Announces Agreement with Adherex in the Field of Cancer.
Microbiotix Appoints Terry L. Bowlin, Ph.D. Chief Scientific Officer.
Valent BioSciences, Libertyville, Ill., enters into a research agreement with the National Research Council of Canada's Plant Biotechnology Institute...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters